Charité Universitätsmedizin Berlin researchers reported the first documented instance of a sustained, treatment-free HIV remission after allogeneic stem-cell transplantation (allo-SCT) in a recipient who lacked complete resistance to HIV. The study challenges long-held assumptions about HIV suppression and renews interest in strategies that focus on reservoir elimination and immune clearance.
From “het” to “het”
For many years, the CCR5Δ32 mutation, which blocks a key HIV co-receptor on immune cells, has been considered crucial for any cure achieved through allo-SCT. The initial case of the “Berlin patient,” who received donor cells homozygous for CCR5Δ32 , shaped the field’s expectations and rendered many of his immune cells functionally resistant to HIV infection.
However, i

Inside Precision Medicine

America News
Raw Story
Associated Press US and World News Video
The Conversation
Bozeman Daily Chronicle
The Babylon Bee
KUOW Public Radio
CBS News
KCRA News
The Daily Beast